Liquidia (LQDA) said Friday the US Food and Drug Administration approved Yutrepiatm for patients with pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease.
The approval was based on the findings of a phase 3 trial that evaluated the prostacyclin analog's effectiveness in facilitating better exercise ability, according to a statement. The candidate was recorded as safe and well-tolerated.
An argument on a motion filed by United Therapeutics (UTHR) for a restraining order and preliminary injunction to block Liquidia from launching Yutrepia was held on May 20. The motion is pending in court, the company said.
Shares were up 0.8% after resuming trade following a trade halt.
Price: 15.51, Change: -0.05, Percent Change: -0.32
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。